Zeitschrift

Journal of Basic and Clinical Physiology and Pharmacology

Editor-in-Chief: Ugo Oliviero
Managing Editor: Alberto Marra

Sprache: Englisch

Erstveröffentlichung: 1. Dezember 1986

Neuestes Heft anzeigen

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen Erkunden Sie dieses Fachgebiet

Über diese Zeitschrift

Objective
The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including Emergency Medicine, Oncology, Hematology and Coagulation disorders, Vascular Medicine, Gastroenterology, Liver Disease, Neurology and Cerebrovascular Diseases, Gender Medicine, Endocrinology, Diabetology and Metabolism, Cardiovascular Diseases, Heart Failure, Respiratory Disease, Geriatrics, Immunology and Rheumatology.

Moreover, Manuscripts regarding basic and laboratory sciences will be very welcome.

As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes.　

Topics

Emergency Medicine
Oncology
Hematology and Coagulation disorders
Vascular Medicine
Gastroenterology
Liver Disease
Neurology and Cerebrovascular Diseases
Gender Medicine
Endocrinology
Diabetology and Metabolism
Cardiovascular Diseases
Heart Failure
Respiratory Disease
Geriatrics
Immunology
Rheumatology

Article formats
Research Articles, Reviews and Mini Reviews, Short Communications, Editorials and Letters to the Editor

Ihre Vorteile

State-of-the-art research in physiology and pharmacology
Integrative approach to descriptive and behavioral studies
Leading-edge techniques
High quality peer-review

Erfordert eine Authentifizierung Nicht lizenziert
Lizenziert

Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy?

27. November 2025

Saurav Misra, Manmeet Kaur, Ashish Kumar Saranjhna

PDF downloaden

Mirikizumab is a monoclonal antibody that targets the human IL-23p19 and has been humanized with IgG4. It is currently under development for treating Crohn’s disease and ulcerative colitis. The FDA approved mirikizumab on October 26, 2023 as a highly effective treatment for ulcerative colitis, providing patients with a new option for this chronic and debilitating inflammatory bowel disease. Millions of people worldwide suffer from ulcerative colitis, and it is crucial to induce and maintain remission. However, existing therapies may not suffice in terms of efficacy or patient tolerability. Mirikizumab demonstrated a favorable safety profile during trials, with reported adverse events aligning with anticipated outcomes in the patient group. These safety results underscore the viability of mirikizumab as a well-tolerated therapeutic option for extended use. The trials data indicated that the treatment not only swiftly alleviated symptoms but also exhibited potential for sustaining remission over an extended period. This article seeks to offer a condensed overview of the noteworthy clinical trial outcomes that contributed to the development of mirikizumab, ultimately leading to its initial approval for the treatment of ulcerative colitis.
Erfordert eine Authentifizierung Nicht lizenziert
Lizenziert

Physiological belching during impedance-pH monitoring: a meal with Coca-Cola provokes a prompt gastroesophageal reaction with increased prandial belching

21. Juli 2025

Alessandra B. Melchior, Martina E. Da Cas, Nicolle Surkamp, Victória Zamprogna, Matheus P. Silveira, Tarcisio S. Santos, Lucas Z. Montenegro, Luiza M. Volpi, Fernando Fornari

PDF downloaden

Objectives To assess the belching-related esophageal events in healthy volunteers during and after fast-food meals. Methods Ten adult healthy volunteers had two lunches with a Big Mac ® on different days, accompanied or not by Coca-Cola (500 mL, pH<3) in a random way. We assessed prandial and 2 h postprandial esophageal events using impedance-pH monitoring. Results During meals with Coca-Cola, most signed belching (68 %) were concomitant with prolonged esophageal acidification or acid reflux, and the belching number was superior [median: 9.5 (IQR 4.7–14) vs. 0 (0–3); p=0.002] and less frequently represented by pure gas (24 % vs. 92 %; p<0.001) than in meals without Coca-Cola. Postprandial belching did not differ either in frequency [median: 15.5 (6–20.2) vs. 13.5 (10.7–20.5); p=0.739] or in type [(median %) pure gas: 6.7 % vs. 11.7 %; during acid reflux: 64.6 % vs. 51.7 %; during nonacid reflux: 22.5 % vs. 22.2 %; p=0.300), with more than 80 % of belching coincident with asymptomatic liquid reflux, regardless of Coca-Cola intake. Postprandial gastroesophageal reflux and esophageal acid exposure were similar, irrespective of Coca-Cola intake. Conclusions In healthy volunteers, a fast-food meal with Coca-Cola provoked a prompt reaction with increased prandial belching and esophageal acidification. Coca-Cola did not change postprandial belching, often accompanied by silent gastroesophageal liquid reflux.
Erfordert eine Authentifizierung Nicht lizenziert
Lizenziert

Mental toughness and athletic performance: a narrative review

25. September 2025

Raja Soundara Pandian Pachaiappan, Veera Balajikumar Veeraswamy, Kannan Mahalingam, Gurubharathy Gurusamy, Bijulakshmi Parthiban

PDF downloaden

Background Mental toughness represents a crucial psychological construct in competitive sports. This narrative review examines the relationship between mental toughness and athletic performance across various sports domains. Methods We conducted a comprehensive literature review of empirical studies published between 2000 and 2024. Relevant articles were identified through database searches including PubMed, PsycINFO, SPORTDiscus, and Web of Science. Studies examining mental toughness in relation to performance outcomes in competitive athletes were included. Results Evidence consistently shows positive correlations between mental toughness and athletic performance (r=0.21–0.63). Mental toughness demonstrates stronger associations with performance in individual sports compared to team sports. Additionally, psychological interventions targeting mental toughness components show promise for enhancing athletic outcomes. Conclusions Mental toughness represents a significant psychological factor in athletic achievement. The construct influences performance through multiple pathways including resilience to pressure, emotional regulation, and focus maintenance. Practical applications for coaches and sport psychologists are discussed.
Erfordert eine Authentifizierung Nicht lizenziert
Lizenziert

A prospective study to assess the prognosis of patients with necrotizing fasciitis using laboratory risk indicator for necrotizing fasciitis (LRINEC) scoring system in a tertiary care hospital

17. Dezember 2025

Rekha Walwekar, Vignesh Ramalingam, Arun Walwekar

PDF downloaden

Introduction Necrotizing fasciitis (NF) is a rare but potentially fatal infection, involving the subcutaneous tissue and fascia. The incidence of NF worldwide ranges from 0.30 to 15 cases per 100,000 populations and mortality remains high at 25 %. Objectives To classify severity of necrotizing fasciitis and assess the prognosis of necrotizing fasciitis using the LRINEC Scoring system. Methods A thorough history and detailed clinical examination was done. Patient underwent necessary investigations like hemoglobulin, total leukocyte count, serum sodium, serum creatinine, random blood sugar, and C-reactive protein. Based on the investigations, two groups were formulated, LRINEC score <6 (low risk) and ≥6 (high risk). Then prognosis was assessed. The results were compared between the two groups. Results In our study, a total of 124 patients were included with 62 of them with LRINEC score of <6 and 62 patients with LRINEC score ≥6. The sensitivity and specificity for predicting the septic shock and mortality with LRINEC score is 94 % and 70 % and 94 % and 71 %, respectively. Conclusions LRINEC score is a simple clinical tool for predicting the prognostic outcomes in patients with necrotizing fasciitis. LRINEC score of ≥6 have poorer prognosis in the form septic shock and eventual mortality.
Erfordert eine Authentifizierung Nicht lizenziert
Lizenziert

An overview and comparison of haemovigilance reporting forms across six countries relative to the WHO template

11. Dezember 2025

Manmeet Kaur, Saurav Misra, Jayant Kumar Kairi

PDF downloaden

Objectives Haemovigilance monitors, identifies, reports, investigates, and analyses adverse event near-misses and reactions related to transfusion and blood product manufacture. Methods This was an observational study in which we analyzed and compared the WHO haemovigilance template form for hospital and blood establishment haemovigilance reporting forms from Australia, Canada, India, New Zealand, South Africa, and the United States. All data from these reporting systems/forms was tabulated. The study analyzed data elements from each form, scoring them based on their presence in the WHO template and country forms. Higher scores indicated greater comparability and more comprehensive data collection. Results We identified 57 data fields in haemovigilance reporting forms from six countries and the WHO template, essential for collecting information on suspected transfusion products and reactions. The US FDA form has the most fields at 40 (70 %), followed by Canada with 33 (58 %) and India with 27 (47 %). New Zealand’s form has the fewest at 16 (28 %), followed by South Africa with 17 (30 %). Conclusions Effective haemovigilance systems require time and commitment to develop, often starting small and growing with stakeholder involvement. A straightforward reporting form, accessible to all, is crucial for success.
Erfordert eine Authentifizierung Nicht lizenziert
Lizenziert

The role of the urinary microbiome in diabetes-associated UTIs: current understanding and future directions

19. November 2025

Meenakshi Reddy Yathindra, Rithvika Badugu, Shaurya Kumar Singh, Sowthrisha Paluri, Hrudai Poudala, Naraginti Leninbabu Swathi

PDF downloaden

This review explores the interplay between type 2 diabetes mellitus (T2DM) and urinary microbiome dysbiosis, focusing on its role in urinary tract infections (UTIs). Once considered sterile, the urinary tract hosts a diverse microbiota that supports mucosal immunity and pathogen resistance. In T2DM, chronic hyperglycemia and glycosuria disrupt microbial balance, impair immune responses, and increase UTI susceptibility. Glycosuria promotes pathogenic colonization, biofilm formation, and microbial shifts, with studies reporting a threefold rise in Escherichia coli and a 56 % reduction in Lactobacillus spp. in diabetic women with recurrent UTIs. Diabetic urine shows reduced diversity, higher abundance of Klebsiella , Pseudomonas , and Enterococcus , and elevated IL-8. Microbiota-targeted interventions, including probiotics ( Lactobacillus crispatus , Lactobacillus rhamnosus GR-1), prebiotics (astaxanthin), and phytotherapeutics (cranberry), demonstrate potential via lactic acid, hydrogen peroxide production, competitive exclusion, and NF-κB modulation. A 12-month RCT showed significant UTI recurrence reduction with probiotics. Advances in 16 S rRNA sequencing and metagenomics reveal microbial signatures associated with diabetic UTIs, though methodological heterogeneity limits comparability. A review of 1,200 publications (2000–2024) highlights the need for longitudinal studies and precision microbiota therapeutics to translate findings into clinical practice.
Erfordert eine Authentifizierung Nicht lizenziert
Lizenziert

Efficacy and safety of Mirikizumab in the treatment of moderate to severe active ulcerative colitis: a systematic review

15. Dezember 2025

Ajay Kumar Shukla, Saurav Misra, Ravi Kant Narayan, Shahnawaz Ahmed

PDF downloaden

Introduction Ulcerative colitis in the second or third decade is characterised by haematochezia, stomach pain, faecal urgency, and tenesmus. On October 26, 2023, the US-FDA approved Mirikizumab for the treatment of moderate-to-severe ulcerative colitis in adults. Content This systematic review evaluated the safety and effectiveness of Mirikizumab for the treatment of ulcerative colitis by analysing data from available clinical trials. We performed a thorough search across databases such as PubMed, Cochrane, Embase, Scopus, Google Scholar, and ClinicalTrials.gov, covering records from their inception up to June 30, 2025, in accordance with PRISMA guidelines. Thorough investigation identified five relevant studies: four randomised controlled trials and one observational study. All Mirikizumab doses achieved complete healing of the inflamed lumen. Except for the 50 mg dose, they also showed superior histological remission compared to placebo. Most adverse effects likely stem from the condition itself rather than the drug, supported by a higher dropout rate among placebo patients. Additionally, in patients with prior treatment failures, Mirikizumab demonstrated improved outcomes by week 40. Summary and Outcome Mirikizumab improves clinical, endoscopic, and histological results in ulcerative colitis. This study highlights the clinical importance of Mirikizumab and its potential to change treatment standards for ulcerative colitis.
Erfordert eine Authentifizierung Nicht lizenziert
Lizenziert

Menopause, estrogen, and GERD: an exploration of symptoms and endoscopic correlations

16. Oktober 2025

Praveena Meyyazhagan, Pavitra Vyshnavi Yogisparan, Thendral Anandaraj

PDF downloaden

Objectives To define the pattern of symptoms and severity of GERD among premenopausal and postmenopausal women in relation to estrogen levels and endoscopy findings. Methods The research was carried out in the Laboratory of Gastrointestinal Motility inside the Gastroenterology Department at PSGIMS&R, Coimbatore and the following approval from Institutional Human Ethics Committee (IHEC). Results The findings reveal significant variations in estrogen levels between premenopausal and postmenopausal women with gastroesophageal reflux disease (GERD), with premenopausal women having higher levels (82.80 ± 27.91 to 150.43 ± 40.80 pg/mL) compared to postmenopausal women (6.05 ± 2.75 to 17.30 ± 5.43 pg/mL, p < 0.001). This decline in estrogen post-menopause is associated with increased GERD symptoms and endoscopic abnormalities. Conclusion The study concludes that reduced estrogen levels in postmenopausal women are linked to a higher prevalence of GERD symptoms, including heartburn and dysphagia, compared to premenopausal women. Endoscopic findings further support the correlation between hormonal changes and GERD severity, highlighting the necessity for careful evaluation of GERD risk factors.

CiteScore	4.2	2024, Scopus (Elsevier B.V., 2025)
SCImago Journal Rank	0.487	2024, SJR (Scimago Lab, 2025; Data Source: Scopus)
Source Normalized Impact per Paper	0.541	2024, CWTS Journal Indicators (CWTS B.V., 2025; Data Source: Scopus)

Journal of Basic and Clinical Physiology and Pharmacology

Übersicht

Über diese Zeitschrift

Ihre Vorteile

Ahead-of-Publication / Just-Accepted

Ausgaben

Metriken

Einreichen

Editorial

Abstracting und Indexing

Zusatzmaterial

Zusatzmaterial

Fachgebiete

Fachgebiete

Externe Links

Bibliographische Daten